# Administration of Venetoclax to Promote Apoptosis of HIV-infected Cells and Reduce the Size of the HIV Reservoir Among People Living With HIV on ART

> **NCT05668026** · PHASE1,PHASE2 · RECRUITING · sponsor: **University of Aarhus** · enrollment: 18 (estimated)

## Conditions studied

- HIV-1-infection

## Interventions

- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT05668026
- **Lead sponsor:** University of Aarhus
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-01
- **Primary completion:** 2026-03-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-04-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05668026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05668026, "Administration of Venetoclax to Promote Apoptosis of HIV-infected Cells and Reduce the Size of the HIV Reservoir Among People Living With HIV on ART". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05668026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*